The early use of Blarcamesine shows promise in treating Alzheimer's, boosting Anavex's potential. Click here to read an ...

Alzheimer’s disease is a progressive form of dementia that accounts for 60% to 80% of dementia cases, with most diagnoses occurring after age 65 years. Symptoms progress from mild memory changes ...

The new test, from Fujirebio Diagnostics, Inc., identifies a sticky brain plaque, known as beta-amyloid, that is a key marker for Alzheimer’s. Previously, the only FDA-approved methods for detecting ...